Ocular Therapeutix (NASDAQ: OCUL) and Hill-Rom (NYSE:HRC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability.
Hill-Rom pays an annual dividend of $0.72 per share and has a dividend yield of 0.8%. Ocular Therapeutix does not pay a dividend. Hill-Rom pays out 36.2% of its earnings in the form of a dividend. Ocular Therapeutix has increased its dividend for 7 consecutive years.
This is a breakdown of current ratings and recommmendations for Ocular Therapeutix and Hill-Rom, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Ocular Therapeutix presently has a consensus target price of $20.67, indicating a potential upside of 269.05%. Hill-Rom has a consensus target price of $92.29, indicating a potential upside of 6.33%. Given Ocular Therapeutix’s stronger consensus rating and higher probable upside, equities analysts plainly believe Ocular Therapeutix is more favorable than Hill-Rom.
Valuation & Earnings
This table compares Ocular Therapeutix and Hill-Rom’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ocular Therapeutix||$1.89 million||87.23||-$44.70 million||($2.28)||-2.46|
|Hill-Rom||$2.74 billion||2.08||$133.60 million||$1.99||43.61|
Hill-Rom has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.
This table compares Ocular Therapeutix and Hill-Rom’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Ocular Therapeutix has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Hill-Rom has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.
Institutional and Insider Ownership
52.9% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 82.3% of Hill-Rom shares are held by institutional investors. 26.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 2.2% of Hill-Rom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Hill-Rom beats Ocular Therapeutix on 10 of the 17 factors compared between the two stocks.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.
Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.